JP2006305390A5 - - Google Patents

Download PDF

Info

Publication number
JP2006305390A5
JP2006305390A5 JP2006223635A JP2006223635A JP2006305390A5 JP 2006305390 A5 JP2006305390 A5 JP 2006305390A5 JP 2006223635 A JP2006223635 A JP 2006223635A JP 2006223635 A JP2006223635 A JP 2006223635A JP 2006305390 A5 JP2006305390 A5 JP 2006305390A5
Authority
JP
Japan
Prior art keywords
metered dose
inhalation formulation
dose inhalation
formulation
metered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006223635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006305390A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006305390A publication Critical patent/JP2006305390A/ja
Publication of JP2006305390A5 publication Critical patent/JP2006305390A5/ja
Pending legal-status Critical Current

Links

JP2006223635A 2002-08-27 2006-08-18 定量吸入処方物を産生するためのプロセス Pending JP2006305390A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40612702P 2002-08-27 2002-08-27
US42243602P 2002-10-30 2002-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004532972A Division JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス

Publications (2)

Publication Number Publication Date
JP2006305390A JP2006305390A (ja) 2006-11-09
JP2006305390A5 true JP2006305390A5 (enExample) 2009-12-03

Family

ID=31981380

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004532972A Expired - Fee Related JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス
JP2006223635A Pending JP2006305390A (ja) 2002-08-27 2006-08-18 定量吸入処方物を産生するためのプロセス
JP2010229135A Withdrawn JP2011046726A (ja) 2002-08-27 2010-10-08 定量吸入処方物を産生するためのプロセス

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004532972A Expired - Fee Related JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010229135A Withdrawn JP2011046726A (ja) 2002-08-27 2010-10-08 定量吸入処方物を産生するためのプロセス

Country Status (14)

Country Link
US (3) US20040042973A1 (enExample)
EP (2) EP1542904B1 (enExample)
JP (3) JP4679901B2 (enExample)
AT (2) ATE384001T1 (enExample)
AU (1) AU2003265639A1 (enExample)
CA (1) CA2495875C (enExample)
CY (1) CY1107376T1 (enExample)
DE (2) DE60318727T2 (enExample)
DK (1) DK1542904T3 (enExample)
ES (1) ES2297262T3 (enExample)
MX (1) MXPA05002248A (enExample)
PT (1) PT1542904E (enExample)
SI (1) SI1542904T1 (enExample)
WO (1) WO2004020289A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
SE0401408D0 (sv) * 2004-06-02 2004-06-02 Astrazeneca Ab Diameter measuring device
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
WO2008097233A1 (en) 2007-02-09 2008-08-14 Schering Corporation Stable pharmaceutical drug aerosols
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
SMT201700066T1 (it) * 2009-05-12 2017-05-08 Galenica Ab Emulsione olio-in-acqua di mometasone
EP2962688B1 (en) 2009-05-12 2020-06-24 Galenica AB Oil-in-water emulsion of mometasone and propylene glycol
AU2015200276B2 (en) * 2010-02-10 2016-01-21 Astrazeneca Uk Limited A filled canister for an inhaler
AU2011214124B2 (en) * 2010-02-10 2014-10-30 Astrazeneca Uk Limited Process for providing a filled canister for an inhaler
CN107626019A (zh) * 2016-07-18 2018-01-26 卓效医疗有限公司 手持式喷雾器
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592319A (en) * 1968-10-28 1971-07-13 Roy S Rousseau Article feed control
US3835898A (en) * 1972-11-13 1974-09-17 Kartridg Pak Co Remotely adjustable filling head
US4793461A (en) * 1987-02-26 1988-12-27 The Kartridg Pak Co. Container feed apparatus
US5143260A (en) * 1990-06-05 1992-09-01 Nozone Dispenser Systems, Inc. Aerosol adapter clamp and power system
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ES2180592T3 (es) * 1991-06-10 2003-02-16 Schering Corp Formulaciones en aerosol libres de clorofluorocarbonos.
US5275212A (en) * 1993-02-24 1994-01-04 Minnesota Mining And Manufacturing Company Aerosol filling method
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5698161A (en) 1996-08-26 1997-12-16 Michigan Critical Care Consultants, Inc. Hollow, multi-dimensional array membrane
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
CN1162157C (zh) * 1996-08-29 2004-08-18 先灵公司 无氯氟烃的糠酸莫米他松气溶胶制剂
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
EP1981545A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products

Similar Documents

Publication Publication Date Title
DK1907037T3 (da) Medikamentdispenser.
EG25113A (en) Inhaler device counter.
JP2006213929A5 (enExample)
IL203915A (en) Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
SI1962933T1 (sl) Inhalator s števcem odmerkov, ki ga sprožimo z vdihom
ZA200802272B (en) Novel dosage formulation
IL200616A0 (en) Co-crystals and pharmaceutical compositions comprising the same
ATE493119T1 (de) Pharmazeutische zusammensetzung
JP2006305390A5 (enExample)
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
DE602006013636D1 (de) Dosiszähler
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
EP1916251A4 (en) ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2156832A4 (en) PHARMACEUTICAL COMPOSITION
ITFI20080016A1 (it) Formulazioni farmaceutiche orali contenenti gliclazide.
JP2008533990A5 (enExample)
EP2305304A4 (en) IMMUNOSTIMULATOR WITH EP1 AGONIST
EP2192122A4 (en) DITHIOLOPYRROLON COMPOUNDS, THEIR PREPARATION AND THEIR USE
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
IL206379A0 (en) 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID ã?-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
IL195148A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof and compositions containing the same
PL2029596T3 (pl) 2-Alkoksy-3,4,5-trihydroksy-alkiloamido-benzotiazepiny, ich wytwarzanie i zastosowanie oraz zawierające je kompozycje